Study drug R-3750 for mild to moderate ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This Phase 1 study tests whether R-3750 is safe in people with mild to moderate ulcerative colitis and looks for early signs it could help. You may be able to join if you have stable treatment, confirmed diagnosis, and meet several health and medication timing rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 to 65 and able to sign consent forms
- Have ulcerative colitis confirmed by colonoscopy and biopsy, with mild to moderate severity
- Be on a stable ulcerative colitis medicine called an aminosalicylate (no dose changes for 4 weeks) and not planning to start other new medicines except the study drug
- For people who can get pregnant and their partners: agree to effective birth control during the study (and stop sperm donation during and for at least 30 days after dosing)
- Be willing to do a flexible sigmoidoscopy if needed (unless you had an endoscopy within 3 months)
- Avoid getting vaccines during the study period
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called MK-8690 for people with moderate to severe ulcerative colitis (UC) who haven't responded well to other treatments or can't tolerate them. The study aims to see if the drug can help control UC symptoms safely.
This trial tests a new drug called SAR442970 for adults with moderate to severe ulcerative colitis (UC) that has not responded well to standard treatments or other advanced therapies. The goal is to see if it can reduce symptoms and improve quality of life.
This trial tests an experimental drug (ISM5411) for people with active ulcerative colitis. The goal is to see if the drug can reduce inflammation and improve symptoms.
This trial tests a new treatment for people with ulcerative colitis (UC) whose disease is active despite taking only mesalamine or sulfasalazine. It aims to find a therapy that can reduce inflammation and improve symptoms.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
This trial tests an experimental drug called R-3750 for people with active Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms.
Hear when a new Ulcerative Colitis Chronic Moderate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.